(Q37836922)

24 August 2017

1 reference

title

Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia (English)

1 reference

24 August 2017

chronic myeloid leukemia

0 references

1 reference

Birgitta Mitchell

1

1 reference

PubMed ID

21299455

24 August 2017

Michael Deininger

series ordinal

2

1 reference

24 August 2017

1 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

52 Suppl 1

1 reference

24 August 2017

4-11

1 reference

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

24 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Gene expression changes associated with progression and response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546916

10.3109/10428194.2010.546916

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21299455